HNSCC is one of the most frequently immune-infiltrated cancer types with Treg, and NK cells.93,102 A recent review has discussed the efficacy of immune checkpoint inhibition in these tumors.93 Within the past few decades, the only targeted therapy that has been approved for HNSCC therapy is the EGFR inhibitor, cetuximab. This evidence concerns the gene EGFR and cancer.